Emanuel Escher
Overview
Explore the profile of Emanuel Escher including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
59
Citations
784
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Alexander S, Christopoulos A, Davenport A, Kelly E, Mathie A, Peters J, et al.
Br J Pharmacol
. 2023 Dec;
180 Suppl 2:S23-S144.
PMID: 38123151
The Concise Guide to PHARMACOLOGY 2023/24 is the sixth in this series of biennial publications. The Concise Guide provides concise overviews, mostly in tabular format, of the key properties of...
2.
Alexander S, Christopoulos A, Davenport A, Kelly E, Mathie A, Peters J, et al.
Br J Pharmacol
. 2021 Sep;
178 Suppl 1:S27-S156.
PMID: 34529832
The Concise Guide to PHARMACOLOGY 2021/22 is the fifth in this series of biennial publications. The Concise Guide provides concise overviews, mostly in tabular format, of the key properties of...
3.
St-Pierre D, Cabana J, Holleran B, Besserer-Offroy E, Escher E, Guillemette G, et al.
Biochem Pharmacol
. 2018 Apr;
154:104-117.
PMID: 29684376
G protein coupled receptors (GPCRs) produce pleiotropic effects by their capacity to engage numerous signaling pathways once activated. Functional selectivity (also called biased signaling), where specific compounds can bring GPCRs...
4.
Mona C, Besserer-Offroy E, Cabana J, Leduc R, Lavigne P, Heveker N, et al.
Org Biomol Chem
. 2016 Nov;
14(43):10298-10311.
PMID: 27752700
A combination of the CXCR4 inverse agonist T140 with N-terminal CXCL12 oligopeptides has produced the first nanomolar synthetic CXCR4 agonists. In these agonists, the inverse agonistic portion provides affinity whereas...
5.
Mona C, Besserer-Offroy E, Cabana J, Lefrancois M, Boulais P, Lefebvre M, et al.
J Med Chem
. 2016 Jul;
59(16):7512-24.
PMID: 27434274
The CXCR4 receptor binds with meaningful affinities only CXCL12 and synthetic antagonists/inverse agonists. We recently described high affinity synthetic agonists for this chemokine receptor, obtained by grafting the CXCL12 N-terminus...
6.
Cabana J, Holleran B, Leduc R, Escher E, Guillemette G, Lavigne P
J Biol Chem
. 2015 May;
290(25):15835-15854.
PMID: 25934394
Biased signaling represents the ability of G protein-coupled receptors to engage distinct pathways with various efficacies depending on the ligand used or on mutations in the receptor. The angiotensin-II type...
7.
Domazet I, Holleran B, Richard A, Vandenberghe C, Lavigne P, Escher E, et al.
Mol Pharmacol
. 2015 Mar;
87(6):982-95.
PMID: 25808928
The octapeptide angiotensin II (AngII) exerts a variety of cardiovascular effects through the activation of the AngII type 1 receptor (AT1), a G protein-coupled receptor. The AT1 receptor engages and...
8.
Sainsily X, Cabana J, Holleran B, Escher E, Lavigne P, Leduc R
Biochem Pharmacol
. 2014 Sep;
92(2):280-8.
PMID: 25175740
The vasoactive urotensin-II (UII), a cyclic undecapeptide widely distributed in cardiovascular, renal and endocrine systems, specifically binds the UII receptor (UT receptor), a G protein-coupled receptor (GPCR). The involvement of...
9.
Sainsily X, Cabana J, Boulais P, Holleran B, Escher E, Lavigne P, et al.
Biochem Pharmacol
. 2013 Oct;
86(11):1584-93.
PMID: 24084430
Urotensin-II (UII), a cyclic undecapeptide, selectively binds the urotensin-II receptor (UT receptor), a G protein-coupled receptor (GPCR) involved in cardiovascular effects and associated with numerous pathophysiological conditions including hypertension, atherosclerosis,...
10.
Fillion D, Cabana J, Guillemette G, Leduc R, Lavigne P, Escher E
J Biol Chem
. 2013 Feb;
288(12):8187-8197.
PMID: 23386604
Breakthroughs in G protein-coupled receptor structure determination based on crystallography have been mainly obtained from receptors occupied in their transmembrane domain core by low molecular weight ligands, and we have...